New HIV combo therapy shows promise in small safety trial
NCT ID NCT05281510
First seen Jan 18, 2026 · Last updated May 12, 2026 · Updated 17 times
Summary
This study tested whether a combination of two lab-made HIV antibodies (VRC07-523LS and CAP256V2LS) followed by an immune-boosting drug (vesatolimod) is safe for women with HIV who are already on standard antiretroviral therapy (ART). The 20 participants were all women from a specific HIV research cohort. The main goal was to check for side effects, not to cure HIV, so participants stayed on their regular HIV medications throughout.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
FRESH Clinical Research Site: Females Rising through Education, Support and Health
Umlazi, 4066, South Africa
Conditions
Explore the condition pages connected to this study.